Careers  |  Sign In  |  Register

Latest in Cardiology

A joint meeting of the Nonprescription Drugs Advisory Committee and the Endocrinologic Drugs Advisory Committee voted 10-2, with one abstention, against recommending OTC use of lovastatin 20 mg in patients considered to be at moderate risk of CHD. References and Resources FDA news Click Here to view...

Risk of myocardial ischemia

Avandia’s New Warning

This update highlights changes to the prescribing information for Avandia including a new boxed warning about the potential increased risk of myocardial ischemia. References and Resources FDA adds a new warning about the risk of myocardial ischemia to the boxed warning for Avandia. Click Here to...

Increased risk of death with Trasylol

Suspension of Proteinase Inhibitor

The FDA announced that Trasylol increases risk of death, and therefore a marketing suspension has occurred. References and Resources FDA Requests Marketing Suspension of Trasylol Click Here to read the update. Sponsored by Thr Doctor's...